CEREBROSPINAL FLUID OXYTOCIN IN SCHIZOPHRENIC AND CONTROL SUBJECTS

精神分裂症患者和对照组受试者的脑脊液催产素

• 批准号: 3781479
• 负责人: D GLOVINSKY
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3781479
• 关键词: antipsychotic agents; cerebrospinal fluid; human subject; neuropharmacology; oxytocin; radioimmunoassay; schizophrenia

Preclinical studies have suggested a link between the neuropharmacology of oxytocin (OT) and changes in behavior, cognition, and neurochemistry associated with schizophrenia. To test these observations clinically, we measured the cerebrospinal fluid OT concentrations of 40 schizophrenic and 15 control subjects using a competitive radioimmunoassay. The CSF OT concentrations of neuroleptic-treated patients were not statistically different from those of the neuroleptic-withdrawn group. No significant differences were found between the mean values of the schizophrenic group and the healthy group.

临床前研究表明神经药理学 催产素（OT）和行为，认知和神经化学的变化 与精神分裂症有关 为了在临床上检验这些观察结果， 本文测定了40例精神分裂症患者脑脊液OT浓度， 和15名对照受试者使用竞争性放射免疫测定法。 脑脊液 抗精神病药治疗患者的OT浓度无统计学差异， 与精神抑制剂戒断组的情况不同。 无显著 精神分裂症组的平均值之间存在差异 健康的一组。